Introduction

Testicular cancer accounts for less than 1% of malignancies in men in the United States, but with an estimated 9,310 new cases in 2018 it remains the most common solid tumor in men aged 20–34 years (1). Testicular germ cell tumors (GCTs), including seminomas and non-seminomas, comprise the majority of testicular neoplasms (>90%) whereas gonadal-stromal tumors represent less than 5% of adult testis tumors (2). While prognosticators and therapeutic strategies for GCTs are well-established and associated with excellent outcomes, patients with rare testicular cancer histologies such as teratomas with somatic-type malignancy and testicular sex cord stromal tumors (TSCST) experience much less favorable outcomes and optimal management paradigms are lacking. The current manuscript will review management strategies for patients with uncommon testicular cancer histologies.

Teratoma with malignant transformation (TMT)

Epidemiology and physiopathology

Teratoma is a common form of GCT containing elements derived from two or more germ-cell layers (endoderm, mesoderm, and ectoderm) and can be classified as mature or immature based on the differentiation of its components (3). TMT is a rare form of teratoma containing somatic type malignant elements encountered in other organs and tissues (4). This entity represents a spectrum of neoplasms including sarcomas [e.g., rhabdomyosarcoma (RMS), malignant nerve sheath tumor], carcinomas [adenocarcinoma (ADC), squamous cell carcinoma (SCC)], hematopoietic malignancies (leukemia) and others
Azizi et al. Uncommon testis cancer histologies

TMT are characterized by invasion of adjacent germ-cell elements by highly atypical somatic cells (13). Authors suggest that the most significant feature for the diagnosis of TMT is expansile proliferation of somatic malignant elements and clinically significant TMT is considered when the somatic-type component fills a field of view at low magnification (4× lens). Thus, assessment of the degree of atypia and the growth pattern of the somatic malignant proliferation by expert genitourinary pathologists is critical for accurate diagnosis and management of patients with TMT.

Outcomes

Experience regarding TMT remains scarce and relies on small case series mainly from high-volume cancer centers (11,14-23) (Table 1). Patients with stage I disease have a favorable prognosis while those with metastatic disease have dismal oncological outcomes despite aggressive surgery and conventional cisplatin-based GCT systemic therapy with historic series from referral centers reporting cancer-specific survival rates in the 50% range (11,15,24).

The largest single-institution TMT series included patients with sarcoma, carcinoma, sarcomatoid yolk sac tumor and nephroblastoma (20). Approximately 75% of the patients presented with stage II–III disease and overall the estimated 5-year cancer-specific survival was 64% (median follow-up 71 months). Predictors of worse survival included high-grade disease, sarcomatoid yolk sac tumor histology, re-operative retroperitoneal lymphadenectomy, and diagnosis of malignant transformation at late relapse. There were no differences in outcomes between sarcoma and carcinoma patients although recurrence patterns differed in that patients with carcinomas relapsed several years later than patients with sarcomas following initial GCT diagnosis.

TMT patients often present with locally advanced disease involving surrounding organs and/or major vessels, which require complex surgical resections and reconstructions in order to achieve durable cure. In the series reported by Rice et al., more than half of the patients (56.2%) required collateral resections, such as nephrectomy, lobectomy, colectomy, neck dissection and aorta/inferior vena cava replacement/grafting (20). Aggressive resection is supported by evidence that negative margins are paramount to achieving long-term remission and superior oncological outcomes (11). Furthermore, compared to patients with GCT, local relapse after initial surgery is much more common with TMT (greater than systemic recurrences), particularly if patients underwent initial treatments in non-specialized centers (37% vs. 13%) (20). When suspected or confirmed, consideration should be given towards referring patients with TMT to high-volume comprehensive cancer centers with expert multidisciplinary care.

Full resection with negative margins is paramount to achieving long term remission. In a 1998 single-institution series, 46 TMT patients with complete resection had significantly improved oncological outcomes during follow-up compared to those with incomplete resection and positive margins (P=0.003) (11).

With a sparse body of literature, there is no established standard of care for TMT, but rather management guidance from high-volume centers. Patients with clinical stage I disease should strongly be considered for primary retroperitoneal lymph node dissection (RPLND) while those with advanced, but resectable disease, are best managed with post-chemotherapy RPLND, multidisciplinary surgical involvement and en bloc resection.
<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Stage at diagnosis</th>
<th>Histology</th>
<th>Significant prognostic factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed et al., 1985 (7)</td>
<td>17</td>
<td>Stage I: 4; stage II: 4; stage III: 9</td>
<td>Sarcoma: 2</td>
<td>None specific</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Spindle-cell sarcoma: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADC: 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LMS: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MEM: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PNET: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RMS: 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SCC: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Others: 4</td>
<td></td>
</tr>
<tr>
<td>Ulbright et al., 1984 (8)</td>
<td>11</td>
<td>NA: 11</td>
<td>Sarcoma: 6</td>
<td>RMS associated with worse survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Nephroblastoma: 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neuroblastoma: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ASC: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MGCT: 1</td>
<td></td>
</tr>
<tr>
<td>Motzer et al., 1998 (11)</td>
<td>46</td>
<td>Stage I: 4; stage II: 20; stage III: 22</td>
<td>Sarcoma: 29</td>
<td>Complete resection vs. incomplete (P=0.003) associated with better survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Others: 17</td>
<td></td>
</tr>
<tr>
<td>Donadio et al., 2003 (12)</td>
<td>10</td>
<td>Stage I: 2; stage II: 2; stage III: 6</td>
<td>Leukemia: 2</td>
<td>Improved outcomes with transformation-oriented CT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADC: 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ASCT: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PNET: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RMS: 4</td>
<td></td>
</tr>
<tr>
<td>El Mesbahi et al., 2007 (14)</td>
<td>14</td>
<td>Stage I: 3; stage II: 2; stage III: 9</td>
<td>Sarcoma: 10</td>
<td>Improved outcomes with transformation-oriented CT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Other sarcomas: 17</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADC: 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BAC: 1</td>
<td></td>
</tr>
<tr>
<td>Corniter et al., 1998 (15)</td>
<td>21</td>
<td>Stage I: 1; stage II–III: 20</td>
<td>Carcinoma: 6</td>
<td>Mediastinal primary, PNET and RMS histologies associated with worse survival</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sarcoma: 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CS: 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LMS: 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MPNST: 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PNET: 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>RMS: 4</td>
<td></td>
</tr>
</tbody>
</table>

Table 1 (continued)
## Table 1  (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Stage at diagnosis</th>
<th>Histology</th>
<th>Significant prognostic factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malagón et al., 2007 (16)</td>
<td>46</td>
<td>Stage I: 4; stage II: 7; stage III: 28; NA: 7</td>
<td>RMS: 29; AS: 6; LMS: 4; HAE: 1; MPNST: 1</td>
<td>Mediastinal primary associated with worse survival</td>
</tr>
<tr>
<td>Necchi et al., 2011 (19)</td>
<td>48*</td>
<td>Stage I: 12; stage II: 24; stage III: 24</td>
<td>Other sarcomas: 15; Nephroblastoma: 2; Carcinoid: 1; ADC: 9; CPT: 1; DCT: 1; HAE: 1; MPNST: 1; PNET: 12; RMS: 12</td>
<td>Stage I–II vs. III (P=0.007), complete resection vs. incomplete (P=0.0005), PNET/ADC vs. other histologies (P=0.022) associated with better survival</td>
</tr>
<tr>
<td>Rice et al., 2014 (20)</td>
<td>121</td>
<td>Stage I: 24; stage II: 43; stage III: 43; NA: 9</td>
<td>Carcinoma: 31; Sarcoma: 59; Sarcomatoid yolk sac: 17; Nephroblastoma: 4; Mixed/others: 10</td>
<td>Diagnosis at late relapse, re-operative RPLND, and high-grade disease associated with worse survival</td>
</tr>
<tr>
<td>Ganjoo et al., 2001 (22)</td>
<td>40</td>
<td>Stage I: 15; metastatic: 25</td>
<td>PNET: 40</td>
<td>Complete resection vs. incomplete associated with better survival</td>
</tr>
<tr>
<td>Guo et al., 2009 (23)</td>
<td>33</td>
<td>Stage I: 7; stage II: 9; stage III: 11; NA: 6</td>
<td>RMS: 17; Other sarcomas: 16</td>
<td>None specific</td>
</tr>
</tbody>
</table>

* some patients had multiple types of malignant transformation. ADC, adenocarcinoma; AS, angiosarcoma; LMS, leiomyosarcoma; MEM, malignant epithelioid mesothelioma; PNET, primitive neuroectodermal tumor; RMS, rhabdomyosarcoma; SCC, squamous cell carcinoma; ASC, adenosquamous carcinoma; MGCT, malignant giant cell tumor; CT, chemotherapy; ASCT, anaplastic small cell tumor; BAC, bronchoalveolar carcinoma; CS, chondrosarcoma; MPNST, malignant peripheral nerve sheath tumor; CPT, choroid plexus tumor; DCT, dendritic cell tumor; HAE, hemangioendothelioma; RPLND, retroperitoneal lymph node dissection; NA, not available.

of visceral and vascular structures when required.

**Systemic therapy**

TMT patients can present with systemic progressive disease and normal serum tumor markers despite adequate treatment with cisplatin-based regimens. Systemic treatment of such cases remains challenging due to their chemo-resistant phenotype. Indeed patients with TMT are unresponsive to conventional GCT regimens and have a propensity for late systemic failure (25). Histology-specific systemic chemotherapy regimens have been suggested as a more effective management strategy for TMT by several authors. In a case series of 10 TMT patients treated...
with regimens tailored to the histology of the somatic malignancy, seven had a partial response including three with a long-term response (12). A similar European study evaluated 8 TMT patients treated with chemotherapy regimens directed to the non-GCT component at relapse and reported a 50% partial response (14). Hence, the optimal management strategy for TMT should comprise resection of all sites of disease with malignant transformation-oriented systemic therapy.

Nonetheless, treatment of TMT remains challenging and effective therapeutic options in advanced disease are still lacking. Gene expression profiling represents a novel approach to better understand molecular mechanisms and identify potential actionable targets in refractory TMT cases (26,27).

**Sarcomas**

GCT transformation with sarcomatous components (SC) is the most common histology among TMT arising from testicular neoplasms and include cases of undifferentiated sarcoma, RMS, and sarcomatoid yolk sac, although other rarer types have been reported [leiomyosarcoma (LMS), angiosarcoma and malignant nerve sheath tumor] (4,11,15,28).

In rare cases, sarcomatous (or sarcomatoid) transformation occurred in GCT patients without teratomatous elements (29). SC can arise in primary testicular tumor, metastases or both, and their GCT clonal origin has been demonstrated (30). Development of SC differentiation after GCT diagnosis often occurs within 2 years after initial treatments (12,20).

When confined to the testis, patients with SC enjoy a favorable prognosis comparable to that of their pure GCT counterparts (23). Conversely, survival rates in patients with metastatic SC have been reported to range from 40–50% with only 10% of patients alive without disease at last follow-up (16). Rice et al. found that tumor grade in sarcomas or sarcomatoid yolk sac cases was an important prognosticator of survival and suggested that more aggressive treatments and more stringent postoperative surveillance be considered for patients with high-grade sarcomatous/sarcomatoid TMT (20). SC are known to be resistant to conventional cisplatin GCT agents and a SC directed regimen consisting of doxorubicin-based chemotherapy is preferred (12). TMT with SC is radiosensitive, thus radiation has little value and is limited to palliation purposes (31).

**PNET**

PNET are categorized as peripheral or central (32). Peripheral PNET carry the Ewing sarcoma (EWS) family of tumors translocations on chromosome 22. Central PNET affects the central nervous system mostly in pediatric patients and does not express the EWS translocations. PNET arising from GCT typically exhibit features of central PNET and can be incorrectly diagnosed as immature teratomas (33,34). Neuroectodermal elements may resemble neuroblastoma, medulloblastoma, peripheral neuroepithelioma or ependymoblastoma (35). Identification of isochromosome 12 in resected tumors supports its GCT origin (36).

TMT patients with PNET do not respond to cisplatin-based chemotherapy but can benefit from a PNET-based systemic regimen of cyclophosphamide, doxorubicin, and vincristine (CAV) alternating with ifosfamide plus etoposide (IE) after retroperitoneal surgery or in patients with unresectable disease (37,38). PNET histology seems to have the best response to systemic therapy in advanced TMT and patients with recurrent advanced PNET may respond to high-dose chemotherapy with stem cell support (12).

**Carcinomas**

Carcinomas such as ADCs, SCC and neuroendocrine carcinomas represent a rare subset of TMT patients (39). Some tumors stain for cytokeratins and carcinoembryonic antigen (CEA) but are negative for GCT markers such as placental alkaline phosphatase (PLAP), alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) (35). Outcomes are based upon stage and resectability of disease (4). Compared to other TMT histologies, carcinomas have a propensity for delayed relapse of 5 years or more from initial GCT diagnosis and seldom respond to fluorouracil-based chemotherapy regimens or radiation (20).

**Malignant TSCST**

**Epidemiology**

TSCST are the second largest group among primary testicular tumors and comprise approximately 5% of all testicular neoplasms (2,40). TSCST originate from Leydig cells, Sertoli cells and other cells from mesenchymal or hematopoietic origin. Pre-pubertal TSCST are usually benign tumors and have no metastatic potential with the exception of undifferentiated tumors (41). Approximately
10% of adult TSCST can be malignant and criteria for malignancy include unfavorable histopathologic features and presence of metastasis (Table 2) (42-46).

A retrospective analysis from National Cancer Database (NCDB) demonstrated that patients with stage I TSCST with malignant features had a lower 5-year survival rate compared to those with stage I testicular GCT (47). Patients with metastatic TSCST have poor survival and these tumors are usually resistant to chemotherapy and radiotherapy (48). Rare occurrence of TSCST and limited clinical data make optimization of treatment strategies for advanced disease challenging. Nevertheless, a recent comprehensive molecular profiling study detected potentially actionable mutations in approximately 40% of adult granulosa cell tumors of the ovary (49). With advancements in the use of high-throughput genomic, epigenomic and proteomic assays, future patients with TSCST could benefit from novel treatments and molecular-guided therapies.

**Malignant Leydig cell tumors**

Leydig cell tumors comprise approximately 3% of all testicular tumors (43). Although they can be seen over a wide age range (2–90 years), they mostly occur in patients between the ages of 30 and 60 years (42,43). Most patients develop a palpable mass (up to 90%), yet 15% of patients present with gynecomastia. Endocrine abnormalities such as precocious puberty in children and sexual dysfunction in adults can be associated with Leydig cell tumors. Bilateral tumors occur in about 2% of all patients and approximately 5% have a history of Klinefelter’s syndrome (50). Most Leydig cell tumors are benign and the prognosis of benign cases is very favorable (51,52). However approximately 10% of Leydig cell tumors are malignant. The aggressive morphologic features associated with metastatic progression in Leydig cell tumors are cytologic atypia, necrosis, angiolymphatic invasion, increased mitotic activity, atypical mitotic figures, infiltrative margins, extension beyond the testicular parenchyma, DNA aneuploidy, and increased Mindbomb-1 (MIB-1) activity (2,42,43).

Testis-sparing surgery (TSS) is a reasonable treatment option for benign Leydig cell tumors (50). In a multicenter retrospective study that included 56 patients with benign Leydig cell tumors with a mean size of less than 15 mm, overall survival rates for patients treated by either radical orchiectomy or TSS were similar. Local recurrence was noted in only 2 (9.5%) patients, both successfully treated with subsequent radical orchiectomy. No metastatic recurrences were observed after a median follow-up of 43 months. TSS is highly recommended for small, ultrasound-detected, non-palpable intraparenchymal testicular lesions according to the European Association of Urology (EAU) guidelines (53). In patients with symptoms of hormonal disorders, immediate orchiectomy was not recommended due to the possibility of an existing benign TSCST. For stage I TSCST cases with rare or no malignant features, treatment with orchiectomy was sufficient and no metastatic recurrence was observed (54). Likewise, patients in a single institutional cohort that consisted of a total of 48 men with TSCST tumors [Leydig cell (28), Sertoli cell (13), granulosa cell (2) and unclassified (5) tumors], 34 patients with no malignant features at partial or radical orchiectomy were successfully observed without undergoing primary RPLND and experienced no tumor recurrence, albeit with limited follow-up (median 14.5 months) (55). Moreover, the accuracy of frozen section examination to differentiate malignant from benign testicular tumor is excellent as reported in a large case series that included 14 patients with Leydig cell tumors (56). A small case series consisting of 18 patients with Leydig cell (16) and Sertoli cell tumors (2) confirmed that none of the patients with low malignant potential on pathological examination relapsed during follow-up (57).

Although 1- and 5-year overall survival rates of patients with malignant appearing stage I Leydig cell tumors are reported as 98% and 91% following orchiectomy, malignant Leydig cell tumors can be lethal when patients present with distant metastases or experience metastatic progression. In one retrospective case series that included 35 benign and 5 malignant testicular Leydig cell tumor cases, death due to disease occurred in 5 (16%) patients after a median follow-up of 4 years (43,47). Older age, symptoms of shorter duration and absence of endocrine manifestations were the clinical features associated with metastasis. Of note, malignant histopathologic features may not be present at the time of orchiectomy in patients that experience metastatic progression following surgery (58,59). Likewise, in a retrospective analysis of 52 patients, age and favorable pathology in the orchiectomy specimens were not absolute for prognosis as one patient with no unfavorable pathological features at the time of orchiectomy died of metastatic disease progression (60). Thus, the presence of metastasis might be the only reliable indicator of malignant behavior in Leydig cell tumors, whereas the presence of favorable histopathological features in the primary tumor does not always preclude the risk of metastatic progression.
<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients [No. of malignant cases]</th>
<th>Histology</th>
<th>Features associated with malignant behavior</th>
<th>Survival outcomes</th>
</tr>
</thead>
</table>
| Cheville et al., 1998 (42) | 22 [8]                                  | Leydig cell tumor                      | Histopathological features similar to Kim et al.  
Plus the following:  
Mitotic rate (≥6 mitoses per 10 HPFs)  
High MIB-1 activity  
Tumor extension beyond testicular parenchyma  
DNA aneuploidy  
Lymphatic invasion  
Metastasis: in 7 malignant cases  
Mean time to metastasis: 14.2 mo. [0–41]  
Cancer specific death: 2 malignant cases  
Mean follow-up: 33.1 mo. [1–127]  
Mean time to death: not reported |
| Kim et al., 1985 (43) | 40 [5]                                  | Leydig cell tumor                      | ≥2 of the following features:  
Tumor size >50 mm  
Infiltrative borders  
Cytological atypia  
Mitotic rate (≥3 mitoses per 10 HPFs)  
Vascular invasion  
Necrosis  
Metastasis: in 5 malignant cases  
Mean time to metastasis: 16 mo. [4–31]  
Cancer specific death: 5 malignant cases  
Mean follow-up: 48 mo. [2–264]  
Mean time to death: 22 mo. [10–31] |
| Young et al., 1998 (44) | 60 [7] (4 with metastasis at diagnosis) | Classic Sertoli cell tumor             | Tumor size >50 mm  
Necrosis  
Moderate to severe nuclear atypia  
Mitotic rate (>5 mitoses per 10 HPFs)  
Vascular invasion  
Metastasis: in 7 malignant cases  
Mean time to metastasis: 68.4 mo. [15–144]  
Cancer specific death: 3 malignant cases  
Mean time to death: 6.3 mo. [1–15]  
Median follow-up: 38 mo. [6–300] |
| Kratzer et al., 1997 (45) | 12 [6] (3 with metastasis at diagnosis) | Large cell calcifying sertoli cell tumor | ≥2 of the following features or any one of the features in patients >25 years  
Tumor size >40 mm  
Gross or microscopic necrosis  
Extra-testicular growth  
Cytological atypia  
Vascular invasion  
Mitotic rate (≥3 mitoses per 10 HPFs)  
Metastasis: in 6 malignant cases  
Mean time to metastasis: 27 mo. [3–54]  
Cancer specific death: 2 malignant cases  
Mean time to death: 32.5 mo. [5–60] |
| Cornejo et al., 2014 (46) | 32 [2]                                  | Adult granulosa cell tumor             | Tumor size >40 mm  
Infiltrative borders  
Lympho-vascular invasion  
Metastasis: in 1 malignant case at 24 mo.  
Cancer specific death: no data  
Mean follow-up (19 cases): 51 mo. [1–169]  
Mean follow-up (19 cases): 51 mo. [1–169] |

TSCST, testicular sex cord stromal tumors; MIB-1, Mindbomb-1; HPF, high-power field.
There currently exist no standardized treatment algorithms for malignant Leydig cell tumors (47). For patients with clinical stage I TSCST with two or more malignant features, primary RPLND is a recognized management strategy. Among six patients who underwent RPLND for clinical stage I disease, four were alive with no evidence of disease at a median follow-up of 6.6 years (55). RPLND revealed pathologic lymph node involvement (pN2) in only one of six cases, however the pN2 patient and one pN0 patient died of disease 24 months following surgery. Mosharafa et al. reported that five clinical stage I patients with two or more malignant features who underwent primary RPLND remained alive with no evidence of disease, none of whom had pathologic node-positive disease at the time of surgery (61). Conversely, four patients with clinical stage I malignant Leydig cell tumors, who were initially observed but later developed retroperitoneal recurrence and subsequently managed with RPLND for clinical stage II–III tumors, died of disease progression (61). Thus, evidence suggests (albeit limited) that a delayed RPLND for retroperitoneal recurrence affords little therapeutic value, although there are reports of patients with low volume stage II TSCST at presentation where RPLND resulted in durable responses (55).

Metastatic spread of malignant Leydig tumors usually occurs within 2 years following primary surgical resection (48). The most common site of metastasis is within the retroperitoneal lymph nodes, whereas distant sites include the lungs, mediastinal and cervical lymph nodes, pelvis, liver, and bone (48,61). For patients with high-volume nodal and distant metastases, management options are limited and survival is dismal. RPLND and metastasectomy offer little therapeutic value and advanced disease is resistant to radiotherapy and cisplatin-based chemotherapy. In a retrospective study that consisted of eight patients with bulky stage II and stage III metastatic tumors who underwent RPLND, median survival was only 1.2 years in spite of aggressive surgical therapy (abdominal and pelvic mass excisions, bowel resection, hepatic lobectomy, and splenectomy) and additional postoperative therapy (radiotherapy in one patient and cisplatin-based combination chemotherapy in five patients) (61). In addition to resistance observed with combination chemotherapy, resistance to other single chemotherapeutic agents was also reported in advanced TSCST cases (48). A steroidogenesis inhibitor (mitotane) was utilized for one patient with increased estradiol (105 pg/mL) and testosterone (2,112 ng/dL) levels at the time of metastatic recurrence. However, response to mitotane was partial and the patient eventually died of disease within nine months (59).

**Malignant sertoli cell tumors**

Sertoli cell tumors comprises approximately 0.5% to 1.5% of all testicular tumors (62). The mean age at diagnosis is 45 years (range, 15–80 years) (44). Patients most often manifest a testicular mass whereas hormonal disorders are usually infrequent. Hormonal abnormalities might occur in patients with androgen insensitivity and Peutz-Jeghers syndrome (44,62). In contrast, large-cell calcifying tumor is a distinct subtype of Sertoli cell tumors and it shows a tendency to occur in younger patients (13 to 34 years) and in patients with complex genetic dysplastic syndromes (63). This subtype demonstrates high tumor bilaterality (44%) and tumor multifocality (28%). Other previously defined subtypes of Sertoli cell tumors such as sclerosing and lipid cell variant, however, are no longer considered distinct subtypes in the recent molecular-based tumor classification (40).

Histopathological criteria associated with malignancy in Sertoli cell tumors are quite similar to malignant Leydig cell tumors: tumor size of 50 mm or greater, necrosis, moderate to severe nuclear atypia, vascular invasion and a mitotic rate of more than five mitoses per 10 high-power fields (HPFs) (44,45). Moreover, Leydig cell tumors with abundant sclerosing stroma appear to metastasize less frequently than more cellular forms (40,62). In a large case series that consisted of 60 patients with Sertoli cell tumors, four patients with malignant tumors had metastasis at initial diagnosis. Additional three patients with malignant tumors developed metastasis subsequently. Among patients with at least 5 years of follow-up, all of the nine patients with benign tumors still remained free of disease and four patients with malignant tumors were still alive with disease. However, two patients who had metastasis at presentation and one patient who developed subsequent metastasis eventually died of disease. Although extremely rare, malignant Sertoli cell tumors have been reported in pre-pubertal patients (64,65). Metastatic progression can occur in the absence of malignant features such as significant pleomorphism or mitosis (64). Thus, neither pre-pubertal status nor histopathological features are sufficient enough to exclude metastasis risk.

Most clinical data regarding management and survival outcomes of malignant Sertoli cell tumors come from small retrospective studies that incorporate all TSCTS types...
Treatment, malignancy criteria and follow-up of Sertoli cell tumors are all similar to Leydig cell tumors. In a retrospective analysis of the NCDB, 84% of patients diagnosed with clinical stage I malignant Sertoli cell tumors were treated with radical orchiectomy alone, and the remaining 16% were additionally treated either RPLND, chemotherapy or radiotherapy (47). For 14 patients with stage II/III Sertoli cell tumors, management varied greatly and involved RPLND, chemotherapy or radiotherapy. However, the 5-year overall survival rate for patients with malignant stage I Sertoli cell tumors (77%) was significantly lower than the 5-year overall survival rate for patients with malignant stage I Leydig cell tumors (91%) and stage I seminomas (98%) (47,66). Thus, it was suggested that primary RPLND should be the mainstay of therapy for malignant Sertoli cell tumors, even for stage I disease (47). Whether Sertoli cell tumors exhibit more aggressive biological behavior than other TSCST is undetermined. However, overall survival rates reveal an inferior trend. Thus, patients diagnosed with malignant Sertoli cell tumors should receive sufficient treatment and meticulous follow-up.

Granulosa cell tumors

There are less than 150 reported cases of testicular Granulosa cell tumor (46,67,68). Based on disease onset, they are grouped in two distinct types. Almost 90% of juvenile Granulosa cell tumors occur in infants six months of age or younger (67). All juvenile subtypes show benign behavior despite frequent mitotic activity and they are amenable to TSS. For adult Granulosa cell tumors, mean age at presentation is 40 years (range, 14–87 years) and they mostly occur without endocrine-related symptoms (46). Adult Granulosa cell testicular tumors can show aggressive behavior. Lymphovascular invasion, infiltrative borders, and tumor size of more than 4 cm are features associated with malignant biology. However, most testicular Granulosa cell tumor cases can be managed with radical orchiectomy alone, yet regional lymph node metastasis when present has been reported to respond completely to induction cisplatin-based chemotherapy similarly to conventional GCT types (46,68).

Miscellaneous tumors

Some tumors consist of two or more sex cord stromal elements (mixed sex cord stromal tumors) and can show malignant behavior (40). Gonadoblastoma consists of two distinct components, small sex cord cells and germ cell nests, and 40% of such cases involve both testicles (40,69). Over 50% of gonadoblastoma cases progress to dysgerminoma/seminoma and some of them were reported to have malignant pelvic masses at presentation, thus immediate bilateral orchiectomy/gonadectomy is recommended soon after diagnosis (70,71). Testicular fibrothecomas are other distinct TSCST types that are uniformly benign and no testicular fibrothecoma recurrence has been reported following surgical resection (72). There are also several miscellaneous testicular tumors which are extremely rare and difficult to distinguish from other testicular tumors by imaging and clinical examination (40,73). Tumor-like lesions of ovarian common epithelial types can arise from testis, tunica vaginalis and paratesticular tissues; and some types such as clear cell ADC can show malignant behavior (73,74). Albeit rare, 50% of patients with rete testis carcinomas present with metastasis (75). Management includes radical orchiectomy and RPLND after confirmation of diagnosis; however approximately 40% of patients die within one year and chemotherapy is ineffective.

Surveillance strategies

The optimal follow-up strategy for TSCST remains unknown. Although most metastatic events are reported to occur within 2 years in patients with malignant Leydig cell tumors, metastases have occurred as late as nine years following excision of the primary tumor (48,59). Delayed metastases (seven years following orchiectomy) have even been reported in cases where the primary tumor is devoid of malignant features (59). Although endocrinological abnormalities are more common in benign cases, some patients with malignant Leydig cell tumors have altered steroidogenesis involving hormones such as testosterone, luteinizing hormone, estrone and androstenedione (43,76-78). Moreover, delayed recurrence of malignant testicular Leydig cell cancer confirmed by RPLND was detected resulting from elevated serum estradiol levels (79). Thus, assessment of the pituitary/gonadal axis at both initial and also follow-up visits is reasonable. Of note, GCT markers [AFP, HCG and lactate dehydrogenase (LDH)] were reported as negative for all TSCST in previous case series and routine assessment during follow-up is not indicated (52,62,80).

In summary, cancer surveillance in patients with malignant TSCST includes physical examination, radiographic evaluation of the chest, abdomen and pelvis,
and consideration towards intermittent assessment of serum testosterone, estradiol, LH and FSH levels—particularly in patients with functional tumors (59,80). Some authors recommend extending follow-up to 10 to 15 years after surgical resection as late metastatic events, albeit rare, have occurred in patients with TSCST (52,80). Essentially, optimal surveillance for patients with malignant TSCST should be tailored according to the aggressiveness of the disease, health status of the patient and previous treatments received (81).

**Conclusions**

TMT represents an uncommon type of cisplatin-based chemo-refractory GCT with dismal prognosis in patients with advanced stage disease and a propensity for late recurrence. Optimal management for TMT patients involves a multidisciplinary approach at high-volume referral centers with aggressive surgery and histology-tailored systemic therapy. Surgery can be curative in patients with early stage malignant TSCST while those with high-volume metastatic disease have poor outcomes as these tumors are considered chemoradiation resistant. Further prospective studies are critical to better elucidate the carcinogenesis of such uncommon malignant tumors in order to identify actionable targets, new prognosticators and novel therapeutic approaches.

**Acknowledgments**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**References**

58. Huang H, Wang C, Tian Q. Gonadal tumour risk in


